Bosulif (Bosutinib) is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). It works by slowing or stopping the growth of cancer cells.
Bosulif (Bosutinib) is a tyrosine kinase inhibitor. Although it is able to inhibit several tyrosine kinases such as Src, Lyn, and Hck, which are members of the Src-family of kinases, its primary target is the Bcr-Abl kinase. The Bcr-Abl gene is a chimeric oncogene created from the fusion of the breakpoint-cluster (Bcr) gene and Abelson (Abl) tyrosine gene. This chromosomal abnormality results in the formation of what is commonly known as the Philadelphia chromosome or Philadelphia translocation. The Bcr-Abl gene expresses a particular kinase that promotes the progression of CML. A decrease in the growth and size of the CML tumour has been observed following administration of Bosulif (Bosutinib). Bosulif (Bosutinib) did not inhibit the T315I and V299L mutant cells.
Use Bosulif (Bosutinib) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Nausea,vomiting,stomach/abdominal pain, loss of appetite, joint pain, headache, or dizziness may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
Store at room temperature away from moisture and heat.
Before taking Bosulif (Bosutinib), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease, kidney disease.
Bosulif is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.